Neurosurgical procedures

Deep Brain Stimulation Devices Market Size to Reach USD 2,802.6 Million By 2026 at a CAGR of 15.5% - Valuates Reports

Monday, March 1, 2021 - 2:30pm

The global Deep Brain Stimulation Devices Market was valued at USD 881.9 Million in 2018 and is projected to reach USD 2,802.6 Million by 2026, registering a CAGR of 15.5%.

Key Points: 
  • The global Deep Brain Stimulation Devices Market was valued at USD 881.9 Million in 2018 and is projected to reach USD 2,802.6 Million by 2026, registering a CAGR of 15.5%.
  • The potential benefits of deep brain stimulation devices, such as long-term effectiveness and improved postoperative outcome management, are expected to drive the growth of deep brain stimulation device market size.
  • Due to higher acceptance in surgical procedures, the dual-channel deep brain stimulation segment is expected to hold the largest deep brain stimulation device market share.
  • This is due to the use of technologically advanced deep brain stimulation devices in operation theaters and intensive care units, the increasing number of deep brain stimulation surgeries, and the rising prevalence of PD.

Deep Brain Stimulation Devices Market Size to Reach USD 2,802.6 Million By 2026 at a CAGR of 15.5% - Valuates Reports

Monday, March 1, 2021 - 2:30pm

The global Deep Brain Stimulation Devices Market was valued at USD 881.9 Million in 2018 and is projected to reach USD 2,802.6 Million by 2026, registering a CAGR of 15.5%.

Key Points: 
  • The global Deep Brain Stimulation Devices Market was valued at USD 881.9 Million in 2018 and is projected to reach USD 2,802.6 Million by 2026, registering a CAGR of 15.5%.
  • The potential benefits of deep brain stimulation devices, such as long-term effectiveness and improved postoperative outcome management, are expected to drive the growth of deep brain stimulation device market size.
  • Due to higher acceptance in surgical procedures, the dual-channel deep brain stimulation segment is expected to hold the largest deep brain stimulation device market share.
  • This is due to the use of technologically advanced deep brain stimulation devices in operation theaters and intensive care units, the increasing number of deep brain stimulation surgeries, and the rising prevalence of PD.

AlloSource Announces First Patients Implanted With AlloWrap Amniotic Membrane In Clinical Study For Two-Level Anterior Cervical Discectomy And Fusion Procedures

Tuesday, February 23, 2021 - 6:40pm

The primary objective of this study is to obtain evidence of the effectiveness of AlloWrap Amniotic Membrane in the reduction of soft tissue swelling in two-level ACDF procedures.

Key Points: 
  • The primary objective of this study is to obtain evidence of the effectiveness of AlloWrap Amniotic Membrane in the reduction of soft tissue swelling in two-level ACDF procedures.
  • "Though I have performed many successful anterior cervical discectomy and fusion procedures, I am always looking for ways to improve patient outcomes," said Dr. Paul Kim with The Spine Institute of San Diego.
  • AlloSource's AlloWrap is a human amniotic membrane designed to provide a biologic barrier following surgical repair in a multitude of procedures.
  • Founded in 1994, AlloSource is a nonprofit leader in providing allografts that maximize tissue donation to help surgeons heal their patients.

Rimidi and Emory Healthcare Form Strategic Collaboration with Launch of FHIR-based Apps for Orthopedic Surgery and Deep Brain Stimulation

Tuesday, February 23, 2021 - 2:00pm

As an immediate result of the collaboration, Rimidi and Emory Healthcare have developed new patient and provider-facing Fast Healthcare Interoperable Resource or FHIR apps to create a more collaborative and transparent experience for patients undergoing orthopedic surgery , as well as for those referred to the deep brain stimulation (DBS) program for Parkinson's and other neurologic conditions at Emory Healthcare.

Key Points: 
  • As an immediate result of the collaboration, Rimidi and Emory Healthcare have developed new patient and provider-facing Fast Healthcare Interoperable Resource or FHIR apps to create a more collaborative and transparent experience for patients undergoing orthopedic surgery , as well as for those referred to the deep brain stimulation (DBS) program for Parkinson's and other neurologic conditions at Emory Healthcare.
  • These apps bring together clinical data and protocols with patient reported outcomes and education in the context of the patient journey.
  • "Our team envisioned a better patient journey for orthopedic surgery procedures as well as the deep brain stimulation program.
  • In addition to working with Rimidi on the FHIR apps, Emory Healthcare also leverages Rimidi's clinical management platform to manage high acuity patients with chronic cardiometabolic conditions.

Deep Brain Stimulation Devices Market Size Worth $2.3 Billion By 2028: Grand View Research, Inc.

Monday, February 22, 2021 - 8:35am

SAN FRANCISCO, Feb. 22, 2021 /PRNewswire/ -- The global deep brain stimulation devices market size is anticipated to reach USD 2.3 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Feb. 22, 2021 /PRNewswire/ -- The global deep brain stimulation devices market size is anticipated to reach USD 2.3 billion by 2028, according to a new report by Grand View Research, Inc.
  • Surge in incidence of neurological disorders, growing awareness about the deep brain stimulation devices and introduction of technologically advanced products is attributing to the growth of market.
  • Potential benefits of Deep Brain Stimulation (DBS) devices such as long-term benefits and better postoperative outcomes, are anticipated to fuel the market growth.
  • Grand View Research has segmented the global deep brain stimulation devices market on the basis of product, application, end use, and region:
    Deep Brain Stimulation Devices Product Outlook (Revenue, USD Million, 2016 - 2028)
    Deep Brain Stimulation Devices Application Outlook (Revenue, USD Million, 2016 - 2028)

Deep Brain Stimulation Devices Market Size Worth $2.3 Billion By 2028: Grand View Research, Inc.

Monday, February 22, 2021 - 8:35am

SAN FRANCISCO, Feb. 22, 2021 /PRNewswire/ -- The global deep brain stimulation devices market size is anticipated to reach USD 2.3 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Feb. 22, 2021 /PRNewswire/ -- The global deep brain stimulation devices market size is anticipated to reach USD 2.3 billion by 2028, according to a new report by Grand View Research, Inc.
  • Surge in incidence of neurological disorders, growing awareness about the deep brain stimulation devices and introduction of technologically advanced products is attributing to the growth of market.
  • Potential benefits of Deep Brain Stimulation (DBS) devices such as long-term benefits and better postoperative outcomes, are anticipated to fuel the market growth.
  • Grand View Research has segmented the global deep brain stimulation devices market on the basis of product, application, end use, and region:
    Deep Brain Stimulation Devices Product Outlook (Revenue, USD Million, 2016 - 2028)
    Deep Brain Stimulation Devices Application Outlook (Revenue, USD Million, 2016 - 2028)

OrthoPediatrics Corp. Launches Dedicated ApiFix Website to Support Game-Changing Spinal Deformity Correction System for Treating AIS

Thursday, February 18, 2021 - 1:30pm

The new website includes actionable information and convenient links to help anyone understand more about AIS and the potential benefits of the ApiFix procedure.

Key Points: 
  • The new website includes actionable information and convenient links to help anyone understand more about AIS and the potential benefits of the ApiFix procedure.
  • The ApiFixprocedure offers select AIS patients a less invasive, motion-preserving option for achieving curve correction without the permanence of fusion.
  • The ApiFix procedure is a viable treatment alternative to failed bracing, potentially allowing patients to avoid the permanence of spinal fusion surgery.
  • ApiFix, a leader in motion-preserving scoliosis correction, was acquired by OrthoPediatrics in April 2020 and operates as a wholly-owned subsidiary based in Israel.

Precision Spine® Receives FDA 510(K) Clearance for the Dakota ACDF™ Standalone System

Thursday, February 4, 2021 - 3:47pm

Precision Spine, Inc., a medical device company dedicated to Made-in-the-USA manufacturing, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Dakota ACDF Standalone System in the treatment of degenerative disc disease (DDD).

Key Points: 
  • Precision Spine, Inc., a medical device company dedicated to Made-in-the-USA manufacturing, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Dakota ACDF Standalone System in the treatment of degenerative disc disease (DDD).
  • The Dakota ACDF system features a titanium plate polyetheretherketone (PEEK) cage with cortical cancellous screws for maximum support and a generous cavity for autogenous bone graft to help facilitate fusion.
  • The Dakota ACDF System represents another example of how Precision Spine is making good on its commitment to develop surgeon-designed devices that embody the advanced features surgeons need to help improve OR efficiency and achieve positive patient outcomes, said Chris DeNicola, Chief Operating Officer of Precision Spine.
  • Patients should have at least six weeks of non-operative treatment prior to treatment with an intervertebral fusion device such as the Dakota ACDF System.

Synergy Disc® Announces Enrollment of First Patient in US IDE Clinical Trial

Friday, January 29, 2021 - 2:00pm

Synergy Disc Replacement Ltd., a Colorado-based spinal medical device company and wholly owned subsidiary of Synergy Disc Replacement Inc. (SDRi), announced today that it has enrolled the first patient in its U.S. IDE clinical trial.

Key Points: 
  • Synergy Disc Replacement Ltd., a Colorado-based spinal medical device company and wholly owned subsidiary of Synergy Disc Replacement Inc. (SDRi), announced today that it has enrolled the first patient in its U.S. IDE clinical trial.
  • The Synergy Disc trial is a multi-center, prospective, historically controlled study that will be conducted on 175 patients at up to 15 sites in the U.S.
  • This trial is designed to demonstrate that the Synergy Disc is at least as safe and effective as conventional anterior cervical discectomy and fusion in patients with one-level symptomatic cervical degenerative disc disease (DDD).
  • at Austin Neurosurgeons in Austin, Texas has performed the first surgery utilizing the Synergy Disc in the United States.

Innovative Deep Brain Stimulation Device Reads Brain Signals, Allowing For Individualized Treatment For Parkinson's Patients

Thursday, January 7, 2021 - 1:41pm

"Many patients with PD may be good candidates for deep brain stimulation surgery," said neurologist Melita Petrossian, MD, medical director at Pacific Movement Disorders Center, Pacific Neuroscience Institute.

Key Points: 
  • "Many patients with PD may be good candidates for deep brain stimulation surgery," said neurologist Melita Petrossian, MD, medical director at Pacific Movement Disorders Center, Pacific Neuroscience Institute.
  • The new DBS device provides critical feedback to optimize therapy for patients with Parkinson's disease and other movement disorders.
  • "This device allows us to not only deliver therapeutic electrical stimulation to the patient, but to also record activity in the brain.
  • We can adjust the brain stimulation the patient receives based on the data that are recorded by the device and correct the patient's misfiring brain signals.